

Figure 1





Fig 1




BEST AVAILABLE COPY


- 20261 -

BEST AVAILABLE COPY

Figure 5






# Figure 4




Protein Tyrosine Kinase	Residue at Region A	Residue at Region B	Residue at Region C	Residue at Region D	Residue at Region E	Residue at Region F
JAK3	Pro906	Tyr904	Leu905	Met902	Ala986	Asp912
JAK2	Pro933	Tyr931	Leu932	Met929	Gly993	Asp939
JAK1	Pro948	Phe946	Leu947	Met944	Gly1008	Glu954
BTK	Ala478	Tyr476	Met477	Thr474	Ser538	Asn484
SYK	Glu342	Met340	Ala341	Met338	Ser403	Lys348
HCK	Ala342	Phe340	Met341	Ala342	Ala403	Asp348
LYN	Ala323	Tyr321	Met322	Ala323	Ala384	Asp329
IRK	Ala1080	Leu1078	Met1079	Met1076	Gly1149	Ser1086





BEST AVAILABLE COPY




	-	-	-	+	+	+	-	-	-	-	-	-
WIF-P132	-	-	-	-	-	-	.	+	+	+	+	-
WIF-P131	-	-	-	-	-	-	+	+	+	+	-	-
WIF-P154	-	-	-	-	-	-	-	-	-	+	+	+
IL-2	-	+	-	-	+	-	-	+	-	-	+	-
IL-3	-	-	+	-	-	+	-	-	+	-	-	+
Lane	1	2	3	4	5	6	7	8	9	10	11	12

**BEST AVAILABLE COPY**








**E.**





BEST AVAILABLE COPY *b*



D.1 Con

D.2 WHI-P131


BEST AVAILABLE COPY




BEST AVAILABLE COPY


**A**


	LcI;19	SQ20B	M24-MET	WHI-P131	Lane	M	1	2	3	4	5	6	7	8	9	10
Lane	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	
WHI-P79	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	
WHI-P132	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	
WHI-P112	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	
WHI-P111	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	
WHI-P131	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	
WHI-P258	- 0 1 3 10 0 -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	- - - - -	
bp	23,130 -	9,416 -	6,557 -	4,361 -	2,322 -	2,027 -	1,353 -	1,078 -	872 -	603 -	310 -					


**B**

BEST AVAILABLE COPY














BEST AVAILABLE COPY













C. DDE9501+UVE



B. UVB



A. Control

BEST AVAILABLE COPY



BEST AVAILABLE COPY


Control


UVB

UVB + DDE9501

BEST AVAILABLE COPY


Figure  
21







PI(3)K promotes apoptosis in spleen cells

—■— WHI-P131 (n=9)  
 —◇— WHI-P132 (n=9)  
 - - - □ - - Vehicle Control (n=51)  
 —○— Syngeneic (n=19)  
 - - \* - - Irradiation Controls (n= )  
 - - ♦ - - Cyclosporin A (n=15)  
 - - △ - - Methotrexate (n=16)



131, 132 ↑ survival





## WHI-P131 (60 mg/kg/day) - effects on GVHD development


### Cumulative proportion surviving

Group	Cumulative proportion surviving			median survival (d)	Logrank p value vs. Control	vs. WHI-P131
	n	3.0	6.0			
CONTROL	51	90.2 ± 4.2	17.6 ± 5.3	2.0 ± 1.9	4.4	
WHI-P131	9	100 ± 0	77.8 ± 13.9	33.3 ± 15.7	8.2	0.0003
WHI-P132	9	88.9 ± 10.5	11.1 ± 10.5	0 ± 0	4.4	0.485
M thiotrexate	16	93.8 ± 6.1	56.2 ± 12.4	25.0 ± 10.8	63.5	0.0009 0.356
Methotrexate + WHI-P131	13	100 ± 0	76.9 ± 11.7	61.5 ± 13.5	8.7	<0.0001 0.320
Cyclosporine A	15	73.3 ± 11.4	26.7 ± 11.4	13.3 ± 8.8	4.5	0.493 0.029
Cyclosporine A + WHI-P131	15	80.0 ± 10.3	33.3 ± 12.2	20.0 ± 10.3	5.1	0.198 0.067

Methotrexate vs.

Methotrexate + WHI-P131  
**0.062**

20






Figure 29





Figure 50



30

Figure 31






Figure 32




32

Figure 33




33

Figure 21




34

Figure 35




3 5

Figure 36



36

Figure 3/



37






Figure 59




31

Figure 40



40

Figure 41



✓11

